

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7






Figure 7 contd.




9/41

Figure 7 contd.

D**Training cohort****No. at Risk**

	30	25	21	8	4	1	0
Good prognosis							
Poor prognosis	27	12	7	4	0	0	0

E**Validation cohort****No. at Risk**


	53	42	30	22	15	5	4	2	0	0
Good prognosis										
Poor prognosis	45	26	14	9	7	4	3	3	2	0

10/41

Figure 8

A

Stage I:
14-immune gene signature




No. at Risk

Good prognosis	36	34	25	13	8	3	1	1	0
Poor prognosis	19	14	7	4	2	1	0	0	0

B

Stage I:
Grade




No. at Risk

Grade 1+2	37	34	23	12	5	1	0	0	0
Grade 3+4	13	9	6	2	2	1	1	1	0

Figure 8 contd.

C

Stage II: 14-immune gene signature




No. at Risk

Good prognosis	24	19	16	10	6	1	1	0
Poor prognosis	22	8	2	0	0	0	0	0

D

Stage II: Grade



No. at Risk

Grade 1+2	31	19	11	7	5	1	1	0
Grade 3+4	14	8	7	3	1	0	0	0

12/41

Figure 8 contd.


E

Figure 9




Figure 9 contd.




Figure 9 contd.





Figure 10




Figure 10 contd.



B**CXCL10****CCL5**

Figure 10 contd.


C

Figure 10 contd.


D

Figure 10D contd.




Figure 11




Figure 11 contd.




Figure 11 contd.





Figure 11 D contd.






Figure 11 contd.

E**CD3+ T cells**

SNU182		-	+	+	+
IFN-γ+poly(I:C)		-	+	+	+
PBMC	α-CXCR3	-	-	+	-
	α-CCR5	-	-	-	+

CD56+ NK cells

SNU182		-	+	+	+
IFN-γ+poly(I:C)		-	+	+	+
PBMC	α-CXCR3	-	-	+	-
	α-CCR5	-	-	-	+

Figure 12




Figure 12 contd.





Figure 12 contd.



C**CXCL10 vs Activated Caspase 3****D****TLR3 vs Activated Caspase 3**

Figure 12 contd.




Figure 12 contd.




Figure 13




Figure 14




Figure 15





A**Bootstrap_training cohort****Bootstrap_validation cohort**

Figure 15 contd.

B**Bootstrap_Stage I**

No. at Risk		Survival (yrs)								
Good	36	34	25	13	8	3	1	1	0	
Poor	19	14	7	4	2	1	0	0	0	

Bootstrap_Stage II

No. at Risk		Survival (yrs)							
Good	26	19	16	10	6	1	1	0	
Poor	20	8	2	0	0	0	0	0	

Figure 16




Figure 16 contd.





Figure 16 contd.





Figure 17


A

Figure 17 contd..


B

Figure 17 contd.




Figure 18

